Drugs / JS009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05650203 | Mar 2023 → Oct 2025 | cancer-related condition | Shanghai Junshi Bioscience Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-03 | Shanghai Junshi Bioscience Co., Ltd. | Regulatory 君实生物JS009（抗CD112R单抗）临床试验申请获得美国FDA批准 junshipharma.com ↗
北京时间2022年4月3日，君实生物（1877.HK，688180.SH）宣布，由公司独立自主研发的抗CD112R单克隆抗体注射液（项目代号：TAB009/JS009）用于治疗晚期实体瘤的临床试验申请获得美国食品药品监督管理局（FDA）批准。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-04-03 | Shanghai Junshi Bioscience Co., Ltd. | 君实生物JS009（抗CD112R单抗）临床试验申请获得美国FDA批准 junshipharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05650203 ↗ |
| Route | Intravenous | “JS009,18mg/60mg/180mg/600mg/1200mg, JS006, fixed dose 600mg, Toripalimab injection fixed dose 240mg,IV infusion, every 3 weeks (q3w).” NCT05650203 ↗ |